{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:10:42Z","timestamp":1780445442337,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00415-025-13538-7","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:14:25Z","timestamp":1767968065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eculizumab as a rescue therapy in acute-phase aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder"],"prefix":"10.1007","volume":"273","author":[{"given":"Keyi","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"9","key":"13538_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805\u2013815. https:\/\/doi.org\/10.1016\/S1474-4422(07)70216-8","journal-title":"Lancet Neurol"},{"issue":"4","key":"13538_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","volume":"92","author":"BG Weinshenker","year":"2017","unstructured":"Weinshenker BG, Wingerchuk DM (2017) Neuromyelitis Spectrum Disorders. Mayo Clin Proc 92(4):663\u2013679. https:\/\/doi.org\/10.1016\/j.mayocp.2016.12.014","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"13538_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030273","volume":"17","author":"M Jasiak-Zatonska","year":"2016","unstructured":"Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W (2016) The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int J Mol Sci 17(3):273. https:\/\/doi.org\/10.3390\/ijms17030273","journal-title":"Int J Mol Sci"},{"issue":"7","key":"13538_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381(7):614\u2013625. https:\/\/doi.org\/10.1056\/NEJMoa1900866","journal-title":"N Engl J Med"},{"issue":"6","key":"13538_CR5","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ana.26049","volume":"89","author":"DM Wingerchuk","year":"2021","unstructured":"Wingerchuk DM, Fujihara K, Palace J et al (2021) Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol 89(6):1088\u20131098. https:\/\/doi.org\/10.1002\/ana.26049","journal-title":"Ann Neurol"},{"issue":"1","key":"13538_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40478-025-02019-7","volume":"13","author":"KS Given","year":"2025","unstructured":"Given KS, Acker EG, Macklin WB, Carlin D, Owens GP, Bennett JL (2025) Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica. Acta Neuropathol Commun 13(1):129. https:\/\/doi.org\/10.1186\/s40478-025-02019-7","journal-title":"Acta Neuropathol Commun"},{"key":"13538_CR7","doi-asserted-by":"publisher","first-page":"951423","DOI":"10.3389\/fneur.2022.951423","volume":"13","author":"S Chatterton","year":"2022","unstructured":"Chatterton S, Parratt J, Ng K (2022) Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report. Front Neurol 13:951423. https:\/\/doi.org\/10.3389\/fneur.2022.951423","journal-title":"Front Neurol"},{"issue":"1","key":"13538_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10072-023-06971-x","volume":"45","author":"D Gorriz","year":"2024","unstructured":"Gorriz D, P\u00e9rez-Miralles FC, Quintanilla-Bord\u00e1s C, Alcal\u00e1 C, Frasquet M, Casanova B (2024) Eculizumab for a catastrophic relapse in NMOSD: case report. Neurol Sci 45(1):249\u2013251. https:\/\/doi.org\/10.1007\/s10072-023-06971-x","journal-title":"Neurol Sci"},{"issue":"11","key":"13538_CR9","doi-asserted-by":"publisher","first-page":"e73205","DOI":"10.7759\/cureus.73205","volume":"16","author":"M Watanabe","year":"2024","unstructured":"Watanabe M, Masaki K, Tanaka E, Matsushita T, Isobe N (2024) The efficacy of eculizumab in the acute phase of neuromyelitis optica spectrum disorder: a case series study. Cureus 16(11):e73205. https:\/\/doi.org\/10.7759\/cureus.73205","journal-title":"Cureus"},{"issue":"11","key":"13538_CR10","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"issue":"5","key":"13538_CR11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s11547-020-01318-4","volume":"126","author":"M Cellina","year":"2021","unstructured":"Cellina M, Pirovano M, Ciocca M, Gibelli D, Floridi C, Oliva G (2021) Radiomic analysis of the optic nerve at the first episode of acute optic neuritis: an indicator of optic nerve pathology and a predictor of visual recovery. Radiol Med 126(5):698\u2013706. https:\/\/doi.org\/10.1007\/s11547-020-01318-4","journal-title":"Radiol Med"},{"issue":"9","key":"13538_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581\u2013588","journal-title":"N Engl J Med"},{"issue":"2","key":"13538_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gahlen A, Borisow N et al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79(2):206\u2013216. https:\/\/doi.org\/10.1002\/ana.24554","journal-title":"Ann Neurol"},{"issue":"9","key":"13538_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/jcpt.13675","volume":"47","author":"Y Dai","year":"2022","unstructured":"Dai Y, Ni S, Wu F, Guo S, Zhao X, Wang J (2022) ABCB1 gene polymorphisms impact the effect of high-dose intravenous methylprednisolone therapy on optic neuritis associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder. J Clin Pharm Ther 47(9):1379\u20131387. https:\/\/doi.org\/10.1111\/jcpt.13675","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"13538_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Ter Heine R, Moes D et al (2019) Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet 58(7):859\u2013874. https:\/\/doi.org\/10.1007\/s40262-019-00742-8","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"13538_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE (2020) Eculizumab: a review in neuromyelitis optica spectrum disorder. Drugs 80(7):719\u2013727. https:\/\/doi.org\/10.1007\/s40265-020-01297-w","journal-title":"Drugs"},{"key":"13538_CR17","doi-asserted-by":"publisher","first-page":"1645401","DOI":"10.3389\/fimmu.2025.1645401","volume":"16","author":"Q Zhuang","year":"2025","unstructured":"Zhuang Q, Huang W, ZhangBao J et al (2025) Eculizumab for the acute attack of neuromyelitis optica spectrum disorder. Front Immunol 16:1645401. https:\/\/doi.org\/10.3389\/fimmu.2025.1645401","journal-title":"Front Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13538-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13538-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13538-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:57:40Z","timestamp":1773665860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13538-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13538"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13538-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The case study protocol and informed consent procedures were approved by the ethics committee at the\u00a0First Affiliated Hospital of Fujian Medical University. Research related to human use has conformed to all relevant national regulations, institutional policies and the principles of the Declaration of Helsinki. Written informed consent was obtained from individual or guardian participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Patients signed informed consent to publish their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"73"}}